# Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision

> **NCT02167321** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 90 (actual)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** Arm A : standard neoadjuvant chemoradiotherapy group
- **DRUG:** Arm B : adjuvant FOLFOX group

## Key facts

- **NCT ID:** NCT02167321
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2019-05
- **Final completion:** 2021-08
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2021-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02167321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02167321, "Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02167321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*